This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Faraone, S. V. Articles by Zimmerman, B. Search for Related Content PubMed PubMed Citation Articles by Faraone, S. V. Articles by Zimmerman, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Attention Deficit Hyperactivity Disorder Hazardous Substances DB METHYLPHENIDATE Social Bookmarking                         What's this?

An Analysis of Patient Adherence to Treatment During a 1-Year, Open-label Study of OROS® Methylphenidate in Children With ADHD

SUNY Upstate Medical University, faraones{at}upstate.edu

Joseph Biederman, MD

Massachusetts General Hospital

Brenda Zimmerman

McNeil Consumer & Specialty Phamaceuticals

Objective: Treatment adherence is an important aspect of ADHD symptom management, but there are many factors that may influence adherence. Method: This analysis assessed adherence to OROS methylphenidate during a 1-year, open-label study in children. Adherence was defined as the number of days medication was taken divided by the number of days in the study and determined to be high if 75%. Possible clinical and demographic factors associated with adherence, including use of planned medication breaks, were assessed. Results: Mean adherence was 86.4%. It was 91.6% for the subgroup of patients who reported not taking planned medication breaks (n = 252) and 77.7% for the subgroup taking planned medication breaks (n = 155). Overall, 75% of patients showed high adherence. Older age, low starting dose, minority ethnic status, and fewer ADHD symptoms were associated with low adherence. Conclusion: Various factors were found to be associated with low adherence, and the results of this analysis provide guidance to physicians seeking to identify those patients with ADHD most likely not be adherent to stimulant therapy (J. of Att. Dis. 2007; 11(2) 157-166)

Key Words: methylphenidate • attention deficit/hyperactivity disorder • children • treatment

References

• American Academy of Pediatrics. (2001). Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics, 108, 1033-1044.[Abstract/Free Full Text]
• Baren, M., Swanson, J., Wigal, S., Modi, N.B., & Gupta, S.K. (2000). Lack of effect of different breakfast conditions won the pharmacokinetics and efficacy of OROS methylphenidate HCI extended-release tablets in children with ADHD. Pediatric Research, 47, 23A.
• Barkley, R.A., Murphy, K.R., DuPaul, G.I., & Bush, T. (2002). Driving in young adults with attention deficit hyperactivity disorder: Knowledge, performance, adverse outcomes, and the role of executive functioning. Journal of International Neuropsychology Society, 8, 655-672.[CrossRef]
• Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., et al. (2006). A randomized, placebo-controlled trial of OROS-methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 59, 829-835.
• Biederman, J., Monuteaux, M., Mick, E., Spencer, T., Wilens, T., Silva, J., et al. (2006). Young adult outcome of attention deficit hyperactivity disorder: A controlled 10 year prospective follow-up study. Psychological Medicine, 36, 167-179.[CrossRef][Medline] [Order article via Infotrieve]
• Brown, R.T., Amler, R.W., Freeman, W.S., Perrin, J.M., Stein, M.T., Feldman, H.M., et al. (2005). Treatment of attention-deficit/ hyperactivity disorder: Overview of the evidence. Pediatrics, 115, e749-757.[Abstract/Free Full Text]
• Brown, R.T., Borden, K.A., & Clingerman, S.R. (1985). Adherence to methylphenidate therapy in a pediatric population: A preliminary investigation. Psychopharmacology Bulletin, 21, 28-36.[Medline] [Order article via Infotrieve]
• Brown, R.T., Borden, K.A., Wynne, M.E., Spunt, A.L., & Clingerman, S.R. (1987). Compliance with pharmacological and cognitive treatments for attention deficit disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 521-526.[Medline] [Order article via Infotrieve]
• Brown, R.T., Borden, K.A., Wynne, M.E., Spunt, A.L., & Clingerman, S.R. (1988). Patterns of compliance in a treatment program for attention deficit disorder. Journal of Compliance Health Care, 3, 23-29.
• Charach, A., Ickowicz, A., & Schachar, R. (2004). Stimulant treatment over five years: Adherence, effectiveness, and adverse effects. Journal of American Academy Child and Adolescent Psychiatry, 43, 559-567.[CrossRef][Medline] [Order article via Infotrieve]
• Corkum, P., Rimer, P., & Schachar, R. (1999). Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: Impact on enrollment and adherence to a 12-month treatment trial. Canadian Journal of Psychiatry, 44, 1043-1048.[Medline] [Order article via Infotrieve]
• Cox, D.J., Merkel, L., Penberthy, J.K., Kovatchev, B., & Hankin, C.S. (2004). Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 269-275.[CrossRef][Medline] [Order article via Infotrieve]
• Firestone, P. (1982). Factors associated with children's adherence to stimulant medication. American Journal of Orthopsychiatry, 52, 447-457.[Medline] [Order article via Infotrieve]
• Gau, S.S., Shen, H.Y., Chou, M.C., Tang, C.S., Chiu, Y.N., & Gau, C.S. (2006). Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. Journal of Child and Adolescent Psychopharmacology, 16, 286-297.[CrossRef][Medline] [Order article via Infotrieve]
• Gayton, W.F., Bailey, C., Wagner, A., & Hardesty, V.A. (1986). Relationship between childhood hyperactivity and accident proneness. Perceptual and Motor Skills, 63, 801-802.[Medline] [Order article via Infotrieve]
• Greenhill, L.L., Pliszka, S., Dulcan, M.K., Bernet, W., Arnold, V., Beitchman, J., et al. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 26S-49S.[CrossRef][Medline] [Order article via Infotrieve]
• Johnston, C., & Fine, S. (1993). Methods of evaluating methylphenidate in children with attention deficit hyperactivity disorder: Acceptability, satisfaction, and compliance. Journal of Pediatric Psychology, 18, 717-730.[Abstract/Free Full Text]
• Lam, L.T. (2002). Attention Deficit Disorder and hospitalization due to injury among older adolescents in New South Wales, Australia. Journal of Attention Disorders, 6(2), 77-82.[Abstract/Free Full Text]
• Mannuzza, S., Klein, R., Bessler, A., Malloy, P., & LaPadula, M. (1998). Adult psychiatric status of hyperactive boys grown up. American Journal of Psychiatry, 155, 493-498.[Abstract/Free Full Text]
• Marcus, S.C., Wan, G.J., Kemner, J.E., & Olfson, M. (2005). Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine, 159, 572-578.[Abstract/Free Full Text]
• MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry, 56, 1073-1086.[Abstract/Free Full Text]
• Pelham, W.E., Gnagy, E.M., Burrows-Maclean, L., Williams, A., Fabiano, G.A., Morrisey, S.M., et al. (2001). Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics, 107, e105.[Abstract/Free Full Text]
• Pelham, W.E., Gnagy, E.M., Chronis, A.M., Burrows-MacLean, L., Fabiano, G.A., Onyango, A.N., et al. (1999). A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics, 104, 1300-1311.[Abstract/Free Full Text]
• Shaffer, D., Fisher, P., Lucas, C.P., Dulcan, M.K., & Schwab-Stone, M.E. (2000). NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC- IV): Description, differences from previous versions, and reliability of some common diagnoses. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 28-38.[CrossRef][Medline] [Order article via Infotrieve]
• Sleator, E.K., Ullmann, R.K., & von Neumann, A. (1982). How do hyperactive children feel about taking stimulants and will they tell the doctor? Clinical Pediatrics (Phila), 21, 474-479.[Abstract/Free Full Text]
• Spencer, T., Biederman, J., Wilens, T., Faraone, S., Prince, J., Gerard, K., et al. (2001). Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 58, 775-782.[Abstract/Free Full Text]
• Spencer, T., Wilens, T., Biederman, J., Faraone, S.V., Ablon, J.S., & Lapey, K. (1995). A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Archives of General Psychiatry, 52, 434-443.[Abstract/Free Full Text]
• Swanson, J. (1992). School-based assessments and interventions for ADD students. Irvine, CA: K. C. Publishing.
• Swanson, J. (2003). Compliance with stimulants for attention-deficit/hyperactivity disorder: Issues and approaches for improvement. CNS Drugs, 17(2), 117-131.[CrossRef][Medline] [Order article via Infotrieve]
• Swanson, J., Greenhill, L., Pelham, W.E., Wilens, T., Wolraich, M., Abikoff, H.B., et al. (2000). Initiating Concerta (OROS methylphenidate HCl) qd in children with attention-deficit hyperactivity disorder. Journal of Clinical Research, 3, 59-76.[Medline] [Order article via Infotrieve]
• Swanson, J., Lerner, M., Gupta, S., Shoulson, I., & Wigal, S. (2003). Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD: Proof of concept and proof of product studies. Archives of General Psychiatry, 60, 204-211.[Abstract/Free Full Text]
• Thiruchelvam, D., Charach, A., & Schachar, R.J. (2001). Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 922-928.[CrossRef][Medline] [Order article via Infotrieve]
• Trott, G.E., & Badura, F. (2001). Attention and hyperactivity disorder in children. Early detection—preventing social consequences. MMW Fortschritte der Medizin, 143(5), 32-35.[Medline] [Order article via Infotrieve]
• Weiss, G., Hechtman, L., Milroy, T., & Perlman, T. (1985). Psychiatric status of hyperactives as adults: A controlled prospective 15-year follow-up of 63 hyperactive children. Journal of the American Academy of Child and Adolescent Psychiatry, 24, 211-220.
• Wilens, T.E., Biederman, J., Mick, E., Faraone, S.V., & Spencer, T. (1997). Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. Journal of Nervous and Mental Disease, 185, 475-482.[CrossRef][Medline] [Order article via Infotrieve]
• Wilens, T., McBurnett, K., Bukstein, O., McGough, J., Greenhill, L., Lerner, M., et al. (2006). Multisite, controlled trial of OROS Methylphenidate (CONCERTAÆ) in the treatment of adolescents with Attention-Deficit/Hyperactivity Disorder. Archives of Pediatrics and Adolescent Medicine, 160, 82-90.[Abstract/Free Full Text]
• Wilens, T., Pelham, W., Stein, M., Conners, K.C., Abikoff, H., Atkins, M., et al. (2003). ADHD treatment with once daily OROS methylphenidate: Interim 12-month results from long-term open-label study. Journal of American Academy Child and Adolescent Psychiatry, 42, 424-433.
• Wolraich, M., Greenhill, L.L., Pelham, W., Swanson, J., Wilens, T., Palumbo, D., et al. (2001). Randomized controlled trial of OROS Methylphenidate qd in children with Attention Deficit/Hyperactivity Disorder. Pediatrics, 108, 883-892.[Abstract/Free Full Text]

This version was published on September 1, 2007

Journal of Attention Disorders, Vol. 11, No. 2, 157-166 (2007)
DOI: 10.1177/1087054706295663


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Faraone, S. V. Articles by Zimmerman, B. Search for Related Content PubMed PubMed Citation Articles by Faraone, S. V. Articles by Zimmerman, B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Attention Deficit Hyperactivity Disorder Hazardous Substances DB METHYLPHENIDATE Social Bookmarking                         What's this?